VYNE Therapeutics and Yarrow Bioscience Merger Nears Completion: Cash Dividend Distributed, Reverse Stock Split Set, and YB-101 Poised to Advance Autoimmune Thyroid Disease Pipeline
核心洞察
VYNE Therapeutics distributed a special cash dividend of approximately $16.5 million to stockholders on July 23, 2026, fulfilling a key condition of its pending merger with Yarrow Bioscience.
A 1-for-50 reverse stock split is expected on July 24, 2026, with the combined company to begin trading on Nasdaq under the ticker "YARW" following merger close.
The merger brings together VYNE's InhiBET platform and Yarrow's YB-101 (搜索), a potentially first-in-class anti-TSHR (搜索) monoclonal antibody targeting Graves' disease (搜索) and thyroid eye disease (搜索).
VYNE Therapeutics Inc. has taken the final steps toward completing its proposed merger with Yarrow Bioscience, Inc. (搜索), distributing a special cash dividend to stockholders and setting the stage for a reverse stock split ahead of the combined company's debut on Nasdaq under a new identity. The merger, governed by the Agreement and Plan of Merger and Reorganization dated December 17, 2025, as amended, is expected to close early in the week of July 27, 2026, subject to final Nasdaq listing approval.
The special cash dividend, estimated at an aggregate of $16.5 million, or approximately $0.38 per share, was distributed in cash on July 23, 2026, to VYNE stockholders of record as of July 22, 2026. The per-share estimate was based on 42,989,506 shares of common stock and common stock equivalents outstanding as of July 9, 2026. The total actual distribution amount may be higher or lower than the estimate, as determined under the terms of the Merger Agreement.
Reverse Stock Split and Nasdaq Transition
VYNE's 1-for-50 reverse stock split is expected to take effect on July 24, 2026. Following the split, VYNE common stock is expected to begin trading on a post-reverse split basis on The Nasdaq Capital Market on July 27, 2026, under CUSIP Number 92941V407 and ISIN Number US92941V4077. Upon closing of the merger, the combined company will trade under the name "Yarrow Bioscience, Inc. (搜索)" with the ticker symbol "YARW."
Due Bill Procedures for the Cash Dividend
Because the cash dividend per share exceeds 25% of VYNE's stock price on the declaration date, Nasdaq set July 24, 2026, as the ex-dividend date — one business day after the dividend was distributed. A due bill period ran from July 21, 2026, through the payment date of July 23, 2026. During this period, trades of VYNE common stock carried a due bill obligating sellers to deliver the cash dividend to buyers. VYNE has stated it has no obligations for either the amount or the processing of the due bill, which are settled customarily between brokers.
Strategic Rationale: Combining Two Clinical-Stage Pipelines
The merger unites two clinical-stage biotechnology companies with distinct therapeutic focuses. Yarrow Bioscience is developing YB-101 (搜索), a potentially first-in-class anti-thyroid stimulating hormone receptor (TSHR (搜索)) monoclonal antibody. YB-101 is designed to directly and rapidly disrupt the central mechanism underlying both Graves' disease (搜索) and thyroid eye disease (搜索), two autoimmune thyroid conditions with significant unmet medical need.
VYNE brings its proprietary InhiBET platform, comprising differentiated BET inhibitors engineered to overcome the limitations of early-generation BET inhibitors through alternative routes of administration and enhanced selectivity. These assets target inflammatory and immune-mediated conditions.
Stockholder Approval and Next Steps
VYNE stockholders voted on the merger proposal at a special meeting held on July 16, 2026. With stockholder approval secured and the cash dividend now distributed, the final remaining condition is Nasdaq's review and approval of the combined company's listing application. VYNE previously anticipated closing on or about July 24, 2026, but the timeline has been adjusted to early in the week of July 27, 2026, pending that regulatory green light.